Metastatic melanoma – A review of current and future treatment options

Emanual Michael Maverakis, Lynn A. Cornelius, Glen M. Bowen, Tiffany Phan, Falin B. Patel, Sarah Fitzmaurice, Young He, Barbara A Burrall, Christopher Duong, April M. Kloxin, Hawa Sultani, Reason Wilken, Steve R. Martinez, Forum Patel

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette–Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive Tcell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.

Original languageEnglish (US)
Pages (from-to)516-524
Number of pages9
JournalActa Dermato-Venereologica
Volume95
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Melanoma
imiquimod
Interferons
Therapeutics
Interleukin-2
Programmed Cell Death 1 Receptor
Vaccines
Cryotherapy
Dendritic Cells
Bacillus
Radiotherapy
Extremities
Perfusion
Clinical Trials
Neoplasm Metastasis
Ligands
Skin
Injections
Neoplasms

Keywords

  • CTLA-4
  • IL-2
  • PD-1
  • Stage III
  • Stage IV

ASJC Scopus subject areas

  • Dermatology

Cite this

Maverakis, E. M., Cornelius, L. A., Bowen, G. M., Phan, T., Patel, F. B., Fitzmaurice, S., ... Patel, F. (2015). Metastatic melanoma – A review of current and future treatment options. Acta Dermato-Venereologica, 95(5), 516-524. https://doi.org/10.2340/00015555-2035

Metastatic melanoma – A review of current and future treatment options. / Maverakis, Emanual Michael; Cornelius, Lynn A.; Bowen, Glen M.; Phan, Tiffany; Patel, Falin B.; Fitzmaurice, Sarah; He, Young; Burrall, Barbara A; Duong, Christopher; Kloxin, April M.; Sultani, Hawa; Wilken, Reason; Martinez, Steve R.; Patel, Forum.

In: Acta Dermato-Venereologica, Vol. 95, No. 5, 2015, p. 516-524.

Research output: Contribution to journalArticle

Maverakis, EM, Cornelius, LA, Bowen, GM, Phan, T, Patel, FB, Fitzmaurice, S, He, Y, Burrall, BA, Duong, C, Kloxin, AM, Sultani, H, Wilken, R, Martinez, SR & Patel, F 2015, 'Metastatic melanoma – A review of current and future treatment options', Acta Dermato-Venereologica, vol. 95, no. 5, pp. 516-524. https://doi.org/10.2340/00015555-2035
Maverakis, Emanual Michael ; Cornelius, Lynn A. ; Bowen, Glen M. ; Phan, Tiffany ; Patel, Falin B. ; Fitzmaurice, Sarah ; He, Young ; Burrall, Barbara A ; Duong, Christopher ; Kloxin, April M. ; Sultani, Hawa ; Wilken, Reason ; Martinez, Steve R. ; Patel, Forum. / Metastatic melanoma – A review of current and future treatment options. In: Acta Dermato-Venereologica. 2015 ; Vol. 95, No. 5. pp. 516-524.
@article{7211798ddef64c74afe9d0c948a48854,
title = "Metastatic melanoma – A review of current and future treatment options",
abstract = "Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette–Gu{\'e}rin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive Tcell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.",
keywords = "CTLA-4, IL-2, PD-1, Stage III, Stage IV",
author = "Maverakis, {Emanual Michael} and Cornelius, {Lynn A.} and Bowen, {Glen M.} and Tiffany Phan and Patel, {Falin B.} and Sarah Fitzmaurice and Young He and Burrall, {Barbara A} and Christopher Duong and Kloxin, {April M.} and Hawa Sultani and Reason Wilken and Martinez, {Steve R.} and Forum Patel",
year = "2015",
doi = "10.2340/00015555-2035",
language = "English (US)",
volume = "95",
pages = "516--524",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "5",

}

TY - JOUR

T1 - Metastatic melanoma – A review of current and future treatment options

AU - Maverakis, Emanual Michael

AU - Cornelius, Lynn A.

AU - Bowen, Glen M.

AU - Phan, Tiffany

AU - Patel, Falin B.

AU - Fitzmaurice, Sarah

AU - He, Young

AU - Burrall, Barbara A

AU - Duong, Christopher

AU - Kloxin, April M.

AU - Sultani, Hawa

AU - Wilken, Reason

AU - Martinez, Steve R.

AU - Patel, Forum

PY - 2015

Y1 - 2015

N2 - Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette–Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive Tcell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.

AB - Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette–Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive Tcell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.

KW - CTLA-4

KW - IL-2

KW - PD-1

KW - Stage III

KW - Stage IV

UR - http://www.scopus.com/inward/record.url?scp=84928158616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928158616&partnerID=8YFLogxK

U2 - 10.2340/00015555-2035

DO - 10.2340/00015555-2035

M3 - Article

C2 - 25520039

AN - SCOPUS:84928158616

VL - 95

SP - 516

EP - 524

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 5

ER -